[en] Pancreatic ductal adenocarcinoma is the fourth leading cause of cancer death worldwide, with no satisfactory treatment to date. In this study, we tested whether the combined inhibition of cyclooxygenase-2 (COX-2) and class I histone deacetylase (HDAC) may results in a better control of pancreatic ductal adenocarcinoma. The impact of the concomitant HDAC and COX-2 inhibition on cell growth, apoptosis and cell cycle was assessed first in vitro on human pancreas BxPC-3, PANC-1 or CFPAC-1 cells treated with chemical inhibitors (SAHA, MS-275 and celecoxib) or HDAC1/2/3/7 siRNA. To test the potential antitumoral activity of this combination in vivo, we have developed and characterized, a refined chick chorioallantoic membrane tumor model that histologically and proteomically mimics human pancreatic ductal adenocarcinoma. The combination of HDAC1/3 and COX-2 inhibition significantly impaired proliferation of BxPC-3 cells in vitro and stalled entirely the BxPC-3 cells tumor growth onto the chorioallantoic membrane in vivo. The combination was more effective than either drug used alone. Consistently, we showed that both HDAC1 and HDAC3 inhibition induced the expression of COX-2 via the NF-kB pathway. Our data demonstrate, for the first time in a Pancreatic Ductal Adenocarcinoma (PDAC) model, a significant action of HDAC and COX-2 inhibitors on cancer cell growth, which sets the basis for the development of potentially effective new combinatory therapies for pancreatic ductal adenocarcinoma patients.
Research center :
Giga-Cancer - ULiège
Disciplines :
Oncology
Author, co-author :
Peulen, Olivier ✱; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques
Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300 doi:10.3322/caac.20073
Anonymous (2011) Pancreatic cancer in the UK. Lancet 378: 1050 doi: 10.1016/S0140-6736(11)61465-7
Tinari N, de Tursi M, Grassadonia A, Zilli M, Stuppia L, et al. (2012) An epigenetic approach to pancreatic cancer treatment: The prospective role of histone deacetylase inhibitors. Curr Cancer Drug Targets 12: 439-452. doi: 10.2174/156800912800190884
Mottet D, Pirotte S, Lamour V, Hagedorn M, Javerzat S, et al. (2008) HDAC4 represses p21WAF1/Cip1 expression in human cancer cells through a Sp1-dependent, p53-independent mechanism. Oncogene 28: 243-256 doi:10.1038/onc.2008.371
Mottet D, Bellahcène A, Pirotte S, Waltregny D, Deroanne C, et al. (2007) Histone deacetylase 7 silencing alters endothelial cell migration, a key step in angiogenesis. Circ Res 101: 1237-1246 doi:10.1161/CIRCRESAHA.107.149377
Deroanne CF, Bonjean K, Servotte S, Devy L, Colige A, et al. (2002) Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21: 427-136 doi:10.1038/sj.one. 1205108
Fritsche P, Seidler B, Schüler S, Schnieke A, Göttlicher M, et al. (2009) HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut 58: 1399-1409 doi:10.1136/gut.2009.180711
Lehmann A, Denkert C, Budczies J, Buckendahl AC, Darb-Esfahani S, et al. (2009) High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo. BMC Cancer 9: 395 doi:10.1186/1471-2407-9-395
Miyake K, Yoshizumi T, Imura S, Sugimoto K, Batmunkh E, et al. (2008) Expression of hypoxia-inducible factor-1 alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. Pancreas 36: e1-e9 doi: 10.1097/M PA. 0b013e31815f 2c2a
Oualssi M, Sielezneff I, Silvestre R, Sastre B, Bernard JP, et al. (2008) High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas. Ann Surg Oncol 15: 2318-2328 doi:10.1245/s10434-008-9940-z
Khan O, La Thangue NB (2012) HDAC inhibitors in cancer biology: Emerging mechanisms and clinical applications. Immunol Cell Biol 90: 85-94. doi: 10.1038/icb.2011.100
Kim H-J, Bae S-C (2011) Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transi Res 3: 166-179
ZafarSF, Nagaraju GP, El-Rayes B (2012) Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma. Expert Opin Ther Targets 16: 707-718 doi: 10.1517/14728222.2012.691473
de Bono JS, Kristeleit R, Tolcher A, Fong P, Pacey S, et al. (2008) Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. Clin Cancer Res 14: 6663-6673 doi: 10.1158/1078-0432. CCR-08-0376
Gore L, Rothenberg ML, O'Bryant CL, Schultz MK, Sandler AB, et al. (2008) A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res 14: 4517-1525 doi:10.1158/1078-0432.CCR-07-1461
Ellis L, Pili R (2010) Histone deacetylase inhibitors: Advancing therapeutic strategies in hematological and solid malignancies. Pharmaceuticals 3: 2441-2469 doi:10.3390/ph3082441
Bots M, Johnstone RW (2009) Rational combinations using HDAC inhibitors. Clin Cancer Res 15: 3970-3977 doi: 10.1158/1078-0432.CCR-08-2786
Chun SG, Zhou W, Yee NS (2009) Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer. Cancer Biol Ther 8: 19-30. doi: 10.4161/cbt.8.14.8633
Iwahashi S, Ishibashi H, Utsunomiya T, Morine Y, OchirTL, et al. (2011) Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines. J Med Invest 58: 106-109 doi:10.2152/jmi.58.106
Bai J, Demirjian A, Sui J, Marasco W, Callery MP (2006) Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells. Biochem Biophys Res Commun 348: 1245-1253 doi:10.1016/j.bbrc.2006.07.185
Piacentini P, Donadelli M, Costanzo C, Moore PS, Palmieri M, et al. (2006) Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. Virchows Arch 448: 797-804 doi:10.1007/s00428-006-0173-x.
Donadelli M, Costanzo C, Beghelli S, Scupoli MT, Dandrea M, et al. (2007) Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochim Biophys Acta 1773: 1095-1106 doi:10.1016/j.bbamcr.2007.05.002
Richards DA, Boehm KA, Waterhouse DM, Wagener DJ, Krishnamurthi SS, et al. (2006) Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study. Ann Oncol 17: 1096-1102 doi:10.1093/annonc/mdl081
Pili R, Salumbides B, Zhao M, Altiok S, Qian D, et al. (2012) Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. Br J Cancer 106: 77-84 doi:10.1038/bjc.2011.527
Wu S, Li RW, Li W, Li CJ (2012) Transcriptome characterization by RNA-seq unravels the mechanisms of butyrate-induced epigenomic regulation in bovine cells. PLoS ONE 7: e36940 doi:10.1371/journal.pone.0036940
Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, et al. (2003) Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2: 151-163
Wang X, Li G, Wang A, Zhang Z, Merchan JR, et al. (2013) Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells. Mol Carcinog 52: 218-228 doi:10.1002/mc.21846
Sun WH, Chen G-S, Ou XL, Yang Y, Luo C, et al. (2009) Inhibition of COX-2 and activation of peroxisome proliterator-activated receptor gamma synergistically inhibits proliferation and induces apoptosis of human pancreatic carcinoma cells. Cancer Lett 275: 247-255 doi: 10.1016/j. canlet. 2008.10.023
Colby JKL, Klein RD, McArthur MJ, Conti CJ, Kiguchi K, et al. (2008) Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression. Neoplasia 10: 782-796
Mukherjee P, Basu GD, Tinder TL, Subramani DB, Bradley JM, et al. (2009) Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. J Immunol 182: 216-224. doi: 10.4049/jimmunol.182.1.216
Hill R, Li Y, Tran LM, Dry S, Calvopina JH, et al. (2012) Cell intrinsic role of COX-2 in pancreatic cancer development. Mol Cancer Ther 11: 2127-2137 doi: 10.1158/1535-7163. MCT-12-0342
Dumartin L, QuemenerC, Laklai H, Herbert J, Bicknell R, et al. (2010) Netrin-1 mediates early events in pancreatic adenocarcinoma progression, acting on tumor and endothelial cells. Gastroenterology 137: 1595-1606 doi:10.1053/j.gastro.2009.12.061
Peixoto P, Castronovo V, Matheus N, Polese C, Peulen OJ, et al. (2012) HDAC5 is required for maintenance of pericentric heterochromatin, and controls cell-cycle progression and survival of human cancer cells. Cell Death Differ 19: 1239-1252 doi:10.1038/cdd.2012.3
Lamour V, Le Mercier M, Lefranc F, Hagedorn M, Javerzat S, et al. (2010) Selective osteopontin knockdown exerts anti-tumoral activity in a human glioblastoma model. Int J Cancer 126: 1797-1805 doi: 10.1002/ijc.24751
Deryugina El, Quigley JP (2008) Chick embryo chorioallantoic membrane model systems to study and visualize human tumor cell metastasis. Histochem Cell Biol 130: 1119-1130 doi: 10.1007/s00418-008-0536-2
Tan MH, Nowak NJ, Rueyming L (1986) Characterization of a new primary human pancreatic tumor line. Cancer Invest 4: 15-23. doi: 10.3109/07357908609039823
Lieber M, Mazzetta J, Nelson-Rees W, Kaplan M, Todaro G (1975) Establishment of a continuous tumor-cell line (PANC-1) from a human carcinoma of the exocrine pancreas. Int J Cancer 15: 741-747 doi:10.1002/ijc.2910150505
Schoumacher RA, Ram J, lannuzzi MC, Bradbury NA, Wallace RW, et al. (1990) A cystic fibrosis pancreatic adenocarcinoma cell line. Proc Natl Acad Sci U S A 87: 4012-016. doi: 10.1073/pnas.87.10.4012
Detry C, Lamour V, Castronovo V, Bellahcène A (2008) CREB-1 and AP-1 transcription factors JunD and Fra-2 regulate bone sialoprotein gene expression in human breast cancer cells. Bone 42: 422-431 doi:10.1016/j.bone.2007.10.016
Ouaïssi M, Cabrai S, Tavares J, da Silva AC, Mathieu Daude F, et al. (2008) Histone deacetylase (HDAC) encoding gene expression in pancreatic cancer cell lines and cell sensitivity to HDAC inhibitors. Cancer Biol Ther 7: 523-531. doi: 10.4161/cbt.7.4.5480
Mehdi O, Françoise S, Sofia CL, Urs G, Kevin Z, et al. (2012) HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA). Pancreatology 12: 146-155 doi: 10.1016/j. pan. 2012.02.013
Chen LF, Fischle W, Verdin E, Greene WC (2001) Duration of nuclear NF-KB action regulated by reversible acetylation. Science 293: 1653-1657 doi: 10.1126/science. 1062374
Ashburner BP, Westerheide SD, Baldwin AS (2001) The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol 21: 7065-7077 doi: 10.1128/MCB.21.20.7065-7077.2001
Broude EV, Swift ME, Vivo C, Chang BD, Davis BM, et al. (2007) p21Waf1/Cip1/Sdi1 mediates retinoblastoma protein degradation. Oncogene 26: 6954-6958 doi:10.1038/sj.one.1210516
Deer EL, Gonzalez-Hernandez J, Coursen JD, Shea JE, Ngatia J, et al. (2010) Phenotype and genotype of pancreatic cancer cell lines. Pancreas 39: 425-435 doi: 10.1097/M PA. 0b013e3181 d 5963
Turtoi A, Musmeci D, Wang Y, Dumont B, Somja J, et al. (2011) Identification of novel accessible proteins bearing diagnostic and therapeutic potential in human pancreatic ductal adenocarcinoma. J Proteome Res 10: 4302-4313 doi:10.1021/pr200527z
Kumagai T, Wakimoto N, Yin D, Gery S, Kawamata N, et al. (2007) Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer 121: 656-665 doi:10.1002/ijc.22558
Zhou W, Liang IC, Yee NS (2011) Histone deacetylase 1 is required for exocrine pancreatic epithelial proliferation in development and cancer. Cancer Biol Ther 11: 659-670 doi:10.4161/cbt. 11.7.14720
Iwahashi S, Shimada M, Utsunomiya T, Morine Y, Imura S, et al. (2011) Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-a on pancreatic cancer cells. Int J Clin Oncol 16: 671-678 doi:10.1007/s10147-011-0246-y
Jones J, Bertas W, Blaheta RA, Makarevic J, Hudak L, et al. (2008) Modulation of adhesion and growth of colon and pancreatic cancer cells by the histone deacetylase inhibitor valproic acid. Int J Mol Med 22: 293-299 doi: 10.3892/ijmm-00000022
Daniluk J, Liu Y, Deng D, Chu J, Huang H, et al. (2012) An NF-KB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice. J Clin Invest 122: 1519-1528 doi:10.1172/JCI59743DS1
Takahashi H, Li A, Dawson DW, Hines OJ, Reber HA, et al. (2011) Cyclooxygenase-2 confers growth advantage to syngeneic pancreatic cancer cells. Pancreas 40: 453-459 doi:10.1097/MPA.0b013e31820b9733
Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA (1999) Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 59: 4356-4362
Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, et al. (1997) Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib). J Med Chem 40: 1347-1365 doi:10.1021/jm960803q
Padillo FJ, Ruiz-Rabelo JF, Cruz A, Perea MD, Tasset I, et al. (2010) Melatonin and celecoxib improve the outcomes in hamsters with experimental pancreatic cancer. J Pineal Res 49: 264-270 doi:10.1111/j.1600-079X.2010.00791.x
Rosendahl AH, Gundewar C, Said K, Karnevi E, Andersson R (2012) Celecoxib synergizes human pancreatic ductal adenocarcinoma cells to sorafenib-induced growth inhibition. Pancreatology 12: 219-226. doi: 10.1016/j.pan.2012.04.005
Zhang H, Chen P, Bai S, Huang C (2007) The histone deacetylase inhibitor MS-275 induces p21WAF1/Cip1 expression in human Hep3B hepatoma cells. Drug Dev Res 68: 61-70 doi:10.1002/ddr.20167
Ijichi H (2011) Genetically-engineered mouse models for pancreatic cancer: Advances and current limitations. World J Clin Oncol 2: 195 doi: 10.5306/wjco. v2. i5.195
Lee MJ, Lee HS, Kim WH, Choi Y, Yang M (2003) Expression of mucins and cytokeratins in primary carcinomas of the digestive system. Mod Pathol 16: 403-410 doi: 10.1097/01. MP.0000067683.84284.66
Allum WH, Stokes HJ, Macdonald F, Fielding JWL (1986) Demonstration of carcinoembryonic antigen (CEA) expression in normal, chronically inflamed, and malignant pancreatic tissue by immunohistochemistry. J Clin Pathol 39: 610-614. doi: 10.1136/jcp.39.6.610
Jeong S, Lee DH, Lee Jl, Lee JW, Kwon KS, et al. (2005) Expression of Ki-67, p53, and K-ras in chronic pancreatitis and pancreatic ductal adenocarcinoma. World J Gastroenterol 11: 6765-6769
Naito Y, Kinoshita H, Okabe Y, Kawahara R, Sakai T, et al. (2006) CD56 (NCAM) expression in pancreatic carcinoma and the surrounding pancreatic tissue. Kurume Med J 53: 59-62. doi: 10.2739/kurumemedj.53.59
Reid MD, Bagci P, Adsay NV (2013) Histopathologic assessment of pancreatic cancer: Does one size fit all? J Surg Oncol 107: 67-77. doi: 10.1002/JSO.23194
